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64-Slice CT angiography of the abdominal
aorta and abdominal arteries: comparison
of the diagnostic efficacy of iobitridol
350 mgI/ml versus iomeprol 400 mgI/ml
in a prospective, randomised, double-blind
multi-centre trial
Abstract Purpose: The purpose of
this study was to assess the influence
of iodine concentration on diagnostic
efficacy in multi-detector-row com-
puted tomography (MDCT) angiog-
raphy of the abdominal aorta and
abdominal arteries. Methods: IRB
approval and informed consent were
obtained. In this double-blind trial,
patients were randomised to undergo
MDCT angiography of the abdominal
arteries during administration of io-
bitridol (350 mgI/ml) or iomeprol
(400 mgI/ml). Each centre applied its
own technique for delivery of contrast
medium, regardless of iodine con-
centration. Diagnostic efficacy, image
quality, visualisation of the arterial
wall and arterial enhancement were
evaluated. A total of 153 patients
received iobitridol and 154 received
iomeprol. Results: The ability to
reach a diagnosis was “satisfactory” to
“totally satisfactory” in 152 (99.3%)
and 153 (99.4%) patients respectively.
Image quality was rated as being
“good” to “excellent” in 94.7 and
94.8% segments respectively. Similar
results were observed for image qual-
ity of arterial walls (84.3 vs. 83.2%).
The mean relative changes in arterial
enhancement between baseline and
arterial phase images showed no
statistically significant differences.
Conclusion: This study demonstrated
the non-inferiority of the 350 versus
400 mgI/ml iodine concentration, in
terms of diagnostic efficacy, in ab-
dominal MDCT angiography. It also
confirmed the high robustness and
reliability of this technique across
multi-national practices.
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Multi-detector-row computed tomography (MDCT) has
been established as the method of choice for the diagnosis,
treatment planning and follow-up of most diseases of the
abdominal arteries, including the renal [1–4] and visceral
arteries [5, 6] and the aorta [7–9]. In these anatomical
regions, diagnostic invasive arteriography (digital subtrac-
tion angiography, DSA) has steadily been replaced over the
past few years by non-invasive CT angiography and, in
some cases, by non-invasive magnetic resonance (MR)
angiography [10–12].
However, the broad use of MDCTin the clinical routine,
as well as the choice of contrast agent and administration
technique thereof, still remains controversial. Many
authors have shown that the enhancement of the abdominal
arteries is directly correlated to the amount of iodine (not
contrast agent) per second [5, 13], also known as the
“iodine flux”. The higher the iodine flux, the higher the
density will be within the region of interest. On the other
hand, increasing the total amount of iodine could raise
safety issues such as concern of contrast-induced neph-
ropathy (CIN) in at-risk patients. Because a lower total
amount of iodine lowers the risk of CIN [14–16], protocols
for CT angiography should always find a compromise
between the required contrast enhancement and the amount
of iodine injected.
Although many papers have been published about
preferred methods of administering contrast medium,
some questions remain unanswered. It is still unclear as
to what degree of vascular opacification (in Hounsfield
units, HU) is really necessary to obtain diagnostic images;
in other words, does higher density, which can possibly be
reached with more highly concentrated agents and higher
iodine flux, really further improve diagnostic accuracy?
Finally, even injection parameters still need to be
standardised. Fleischmann and Hittmair [5, 17–19] have
shown the advantages of using a biphasic contrast injec-
tion, calculated individually for every patient, in CT
angiography of the abdominal aorta. However, these
studies were performed on single-slice systems with long
acquisition times. With fast imaging, using 64-slice CT
systems, it seems that injection protocols could be made
much easier, and the benefit of a contrast medium with
higher iodine concentrations could be of great importance.
In addition, optimum injection rate, optimum iodine
concentration and optimum total volume of contrast
medium for abdominal CT angiography still need to be
determined.
In the present trial, patients were investigated during the
injection of two different contrast agents with different
iodine concentrations (350 vs. 400 mgI/ml). In contrast to
some recently published papers [20], where patients were
examined with different iodine concentrations but constant
iodine flux rates, the injection protocol in the present study
was not adapted to the iodine concentration of the agent
used. In addition, the various centres participating in the
present trial were to use their own injection protocols. A
lack of relevant differences in diagnostic efficacy, image
quality and arterial contrast enhancement among the
centres will emphasise how stable and easy to perform
abdominal CTangiography is in clinical settings if state-of-
the-art equipment is used.
The aim of this prospective, randomised study was,
therefore, to assess the influence of iodine concentration on
diagnostic efficacy in CT angiography of the abdominal
and visceral arteries.
Materials and methods
Study design and patient enrolment conditions
This study was a non-inferiority,randomised, double-blind,
prospective, multi-centre trial in patients referred for CT
angiography of the abdominal aorta and its branches. Nine
European centres were involved in this trial between
August 2006 and February 2008. The study protocol was
approved by the local Ethics Committees and Competent
Authorities.
As this study was designed to reflect the conditions of
daily routine, patients were included in a consecutive
manner, regardless of the indication for the examination.
Patients between 18 and 85 years of age were eligible for
study participation. A history of previous (open surgical or
endovascular) vascular treatment in the abdomen was not
an exclusion criterion. Patients with haemodynamic
instability, non-compensated heart failure or hypertension
(systolic blood pressure ≥180 mmHg or diastolic blood
pressure ≥110 mmHg) were not included. In addition,
patients with severe renal insufficiency [defined as
estimated creatinine clearance (Cockroft and Gault)
below 30 ml/min], treatment with diuretics or biguanides
within 48 h before CT angiography, known thyrotoxicosis
or a history of hypersensitivity to iodinated contrast agents
were not included. Breast-feeding or pregnant women were
also excluded from participation in this trial.
After providing written, informed consent, patients were
randomised into two examination groups according to a
randomisation list stratified on centres and balanced every
four patients. Patients in the first group were to undergo the
abdominal CT angiography with injection of iobitridol
350 mgI/ml (Xenetix®, Guerbet, Roissy, France); patients
in the second group were to be examined by means of CT
angiography with injection of iomeprol 400 mgI/ml
(Iomeron®, Bracco, Italy).
CT angiography
Allpatientsincludedinthepresentevaluationwerescheduled
to undergo CT angiography of the abdominal aorta and
573abdominal arteries. All examinations were performed on 64-
slice single-source CT systems (two Siemens SOMATOM
Sensation, four General Electrics LightSpeed VCT, two
Philips Brillance 64), and on a dual-source Siemens
SOMATOM Definition used as a single-source.
Imaging protocol
To allow direct measurement of abdominal arterial en-
hancement, the study examination consisted of two steps
including unenhanced imaging of the abdomen followed
by abdominal CTangiography during the arterial first pass.
If clinically indicated, additional venous or late-phase
imaging could also be performed outside the study
protocol.
Study centres were advised to use their own routinely
used imaging protocol for abdominal CT angiography.
Only a maximum allowed volume of 150 ml was
predefined by the study protocol; all additional parameters,
including injection rate and volume, were to be determined
by the investigators. No compensations based on the
different iodine concentrations of the contrast agents being
compared were performed, as the investigators were
blinded to both products. Thus, iodine flux, meaning the
iodine administration per unit of time, was lower in the
group receiving iobitridol than in the group receiving
iomeprol.
MDCT angiography was performed using automatic
bolus detection software (Smart Prep®, Care Bolus®, or
equivalent) to identify peak contrast enhancement and to
launch the acquisition. The whole abdomino-iliac system
from above the suprarenal aorta to the femoral bifurcation
was to be covered in one imaging procedure.
As the study centres were asked to use their own
clinically established examination protocols, the kilo-
voltage (kV) and milliampere seconds (mAs) values
differed among centres as did the average duration of the
examination.
Injection of contrast medium
To ensure contrast agent administration in double-blind
conditions, allocation of patients to one of the two groups
(iobitridol or iomeprol group) and the preparation of the
contrast agent, pump and injection were performed by a
radiographer or nurse who was not involved in the
subsequent evaluation. The contrast agent used was not
identified on the images to allow blinded reading.
Patient follow-up
Clinical safety monitoring started at inclusion and lasted
until 1 h after the end of the examination.
Evaluation
All CT images were assessed on-site by one local
investigator at each participating hospital. The investigator
was blinded to the contrast material used for each patient.
Diagnostic efficacy
Diagnostic efficacy (primary endpoint) of the CT exami-
nation was defined as the level of available information for
diagnosis provided by the MDCT examination. Readers
rated the diagnostic efficacy of the CTangiographies using
a four-point scale ranging from 0, i.e. not satisfactory (“not
providingenoughinformation=complementaryexamination
recommended”), to 3, i.e. totally satisfactory (“providing the
expected information”), with level 1 indicating not satisfac-
tory(“notprovidingalltheexpectedinformation=couldneed
a complementary examination”) and 2 representing satisfac-
tory (“providing sufficient information”). The primary end-
point was calculated within both product groups by a
cumulative proportion of those patients who presented with
satisfactory (level 2) to totally satisfactory (level 3) images,
and then the two product groups were compared.
Image quality according to vascular territories
As one of the secondary study criteria, the quality of
images was evaluated in 16 pre-specified segments from
the aorto-ilio-femoral axis: the suprarenal, the juxtarenal
and the infrarenal aorta; the coeliac axis and its branches;
the superior andinferior mesenteric artery; the right and left
renal artery; the right and left common and external iliac
artery; the right and left hypogastric artery; and the right
and left common femoral artery.
In all of these 16 arterial segments, image quality was
rated according to a four-point scale, i.e. 0 (null), 1 (poor),
2 (good) and 3 (excellent). If the segment was not
delineated by the field of view (FOV), it was counted as
“not applicable”. In the case of a 0 rating or poor quality,
the reason for insufficient quality was indicated. This
endpoint was calculated within both product groups by a
cumulative proportion of vascular segments that presented
with good (2) and excellent (3) image quality, and then the
two product groups were compared.
Quality of vascular wall visualisation
Additionally, the quality of arterial wall visualisation
within the 16 segments defined above was assessed. This
evaluation was focused on changes within the vascular
wall, including internal deposition of thrombotic material
or inflammatory reaction, if present, and used the four-
point scale mentioned above. In the case of a 0 rating or
574poor quality, the reason for this insufficient quality was
indicated. This criterion was calculated within both product
groups by a cumulative proportion of vascular wall
segments that displayed with good (2) and excellent (3)
image quality, and then the two groups were compared.
Quantification of arterial enhancement
As an additional endpoint, arterial enhancement was mea-
sured in eight predefined areas, including the suprarenal and
the infrarenal aorta, the right and left renal artery, the right
and left common iliac artery, and the right and left common
femoral artery, and compared between the two groups. For
measurement purposes, regions of interest (ROIs) were
defined on unenhanced as well as enhanced images in the
sametableposition(Fig.1).Accordingtothestudyprotocol,
the circumference of the ROI should not extend beyond the
internallimitofthearterialwall.Fortheaorta,theROIwasto
be located in the middle of the vessel and for its branches in
the first 2 cm(Fig. 1). The two groups’ average absolute and
relative enhancements were compared.
Clinical safety
In addition to the efficacy evaluation, the safety profile of
bothcontrastagentswasinvestigated,andanyevent,starting
frominclusionuntiltheendofthefollow-upperiod(1hafter
the end of CTangiography), was collected and reported.
Statistical evaluation
Assuming that in the iobitridol group and the iomeprol
group at least 90% of patients would provide CT images
with a satisfactory to totally satisfactory level of diagnostic
information [21, 22], non-inferiority was defined as a
difference between the two products (Δ =P iobitridol -
Piomeprol) that was statistically higher than the clinical non-
inferiority limit set at Δ0=−10% in the study (maximum
negative difference allowed between iobitridol and iome-
prol). The study was to be demonstrative if the 95%
confidence interval of the difference excluded the
Δ0=−10% clinical non-inferiority limit.
Before starting the trial, the sample size of the study (310
patients)wascalculatedsothatthenon-inferiorityofiobitridol
(350 mgI/ml) in providing the same level of diagnostic
information as iomeprol (400 mgI/ml) could be statistically
demonstrated with 80% power and 5% type-one error.
Confidence intervals and associated P values were
computed for the estimated parameters based on the
asymptotic normality of maximum likelihood estimators
and using the Wald χ
2 statistics in the SAS Genmod
procedure. This procedure computes a generalised linear
model, particularly suitable for adjusting on covariates and
modelling clustered data (assessments at segment level
nested in patients in the present study). In addition, the exact
confidenceintervalandexactPvaluewerealsocomputedfor
the primary endpoint using StatXact software (Cytel
Statistical Software & Services).
Results
Baseline characteristics and examination protocol
In total, 310 patients (247 men and 63 women; mean age:
66.5 years old) referred for CT angiography of the
Fig. 1a, b Principle of the measurement of arterial enhancement in
the region of the suprarenal aorta, demonstrated in a patient
examined with administration of 100 ml iobitridol because of
infrarenal aortic aneurysm. Region of interest (ROI) is defined at
the same table position in the baseline examination (a)a sw e l la si n
the arterial phase images (b), as round surfaces in the lumen of the
vessel, the circumference of which should not extend beyond the
internal limit of the arterial wall
575abdominal aorta and/or the abdominal arteries were
enrolled in this trial. The baseline characteristics of the
study population were well balanced between groups
(Table 1).
Indications for CT included post-surgical follow-up
(56.5%), pre-therapeutic assessment (36.1%) or other
indications (7.4%), such as staging of lymphomas or gastric
carcinomas. At the time of examination, 92 patients had
various clinical symptoms, including hypertension (11.9%),
limb ischaemia (10.7%), abdominal pain (9.4%) or other
(5.5%).Moreover,129patientshadahistoryofendovascular
and/or surgical treatment of abdominal arteries (66 in the
iobitridol group and 63 in the iomeprol group).
Of the 310 patients included, 154 were randomly
assigned into the iobitridol group, and 156 into the
iomeprol group, and only 1 patient was not injected for
technical reasons.
Most of the centres (n=6) performed the CT angiogra-
phies at a fixed tube voltage of 120 kV; the others at either
100 or 120 kV. The mean mAs used was 319.0 (range 63–
896 mAs). No differences could be noticed between groups
for those two parameters.
As shown in Table 2, four centres (accounting for 149
patients or 48% overall) injected the same fixed volume of
contrast material at a fixed injection rate, regardless of
the patient’s weight or indication for the examination. The
other five centres adjusted the injection protocol to the
patient’s condition. Between 63 and 140 ml of contrast
agent were injected at a rate of 2.5–6 ml/s. On average,
patients received 101.0 ml in the iobitridol group and
101.5 ml in the iomeprol group corresponding respectively
to 35.4 and 40.6 g iodine, indicating that there was no
additional volume injected to balance the lack of iodine in
the iobitridol group.
The average duration of the examination (from time of
injection to the end of CT) ranged from less than 1 min up
to 14 min (mean of all centres: 1 min 22 s; standard
deviation: 1 min 37 s).
Overall diagnostic efficacy
Of the 310 patients included, 3 were excluded from the
efficacy analysis for technical reasons (1 in the iobitridol
group and 2 in the iomeprol group).
Of the 307 patients available for further evaluation,
diagnostic efficacy was rated satisfactory or totally satisfac-
toryin152patients(99.3%)oftheiobitridolgroupandin153
patients (99.4%) of the iomeprol group. Non-inferiority was
statistically demonstrated between the two products (exact
Table 1 Demographic data of the study population
Iobitridol 350 (n=154) Iomeprol 400 (n=156) All (n=310)
Sex
Male 115 (74.7%) 132 (84.6%) 247 (79.7%)
Female 39 (25.3%) 24 (15.4%) 63 (20.3%)
Age (years)
n 154 156 310
Mean (SD) 65.2 (10.9) 67.8 (9.8) 66.5 (10.4)
Median 66.0 69.0 68.0
Min/max 30.0 90.0 35.0 86.0 30.0 90.0
Height (cm)
n 154 156 310
Mean (SD) 172.4 (8.8) 172.1 (8.1) 172.2 (8.5)
Median 172.5 172.0 172.0
Min/max 150 196 152 193 150 196
Weight (kg)
n 154 156 310
Mean (SD) 78.5 (16.1) 79.4 (15.7) 78.9 (15.9)
Median 79.0 78.5 79.0
Min/max 44.0 122.0 41.0 130.0 41.0 130.0
Body mass index (kg/m
2)
n 154 156 310
Mean (SD) 26.3 (4.3) 26.7 (4.5) 26.5 (4.4)
Median 26.4 26.0 26.1
Min/max 17.6 39.4 16.7 40.5 16.7 40.5
576Table 2 Injection protocols by centre and overall
Centre (n patients) Volume (ml) Iodine (g) Flow rate (ml/s)
Mean Min Max Mean Min Max Mean Min Max
Centre 1
Total (39) 100 100 100 37.4 35 40 5.0 4.0 5.0
Iobitridol (20) 100 100 100 35 35 35 5.0 4.0 5.0
Iomeprol (19) 100 100 100 40 40 40 5.0 5.0 5.0
Centre 2
Total (40) 120 120 120 45 42 48 3.0 3.0 3.0
Iobitridol (20) 120 120 120 42 42 42 3.0 3.0 3.0
Iomeprol (20) 120 120 120 48 48 48 3.0 3.0 3.0
Centre 4
Total (35) 90 90 90 33.8 31.5 36 3.5 3.5 3.5
Iobitridol (17) 90 90 90 31.5 31.5 31.5 3.5 3.5 3.5
Iomeprol (18) 90 90 90 36 36 36 3.5 3.5 3.5
Centre 7
Total (35) 100 100 100 37.6 35 40 3.0 3.0 3.0
Iobitridol (17) 100 100 100 35 35 35 3.0 3.0 3.0
Iomeprol (18) 100 100 100 40 40 40 3.0 3.0 3.0
Centre 3
Total (38) 89.7 80 140 33.7 28 56 4.8 2.5 5.3
Iobitridol (19) 88.9 80 90 31.1 28 31.5 4.9 4.0 5.2
Iomeprol (19) 90.5 80 140 36.2 32 56 4.6 2.5 5.3
Centre 5
Total (27) 117.8 100 120 44.1 35 48 4.0 4.0 4.0
Iobitridol (14) 117.1 100 120 41 35 42 4.0 4.0 4.0
Iomeprol (13) 118.5 100 120 47.4 40 48 4.0 4.0 4.0
Centre 6
Total (30) 115.4 63 120 43.4 25.2 48 5.0 5.0 5.0
Iobitridol (14) 117.1 100 120 41 35 42 5.0 5.0 5.0
Iomeprol (16) 113.9 63 120 45.6 25.2 48 5.0 5.0 5.0
Centre 8
Total (26) 110.4 74 135 41.4 28 51.2 5.5 4.5 6.0
Iobitridol (13) 110.8 80 135 38.8 28 47.3 5.4 4.5 6.0
Iomeprol (13) 109.9 74 128 44 29.6 51.2 5.5 5.0 6.0
Centre 9
Total (39) 77.4 70 140 29 24.5 56 4.0 4.0 4.2
Iobitridol (20) 76 70 140 26.6 24.5 49 4.0 4.0 4.2
Iomeprol (19) 78.9 70 140 31.6 28 56 4.0 4.0 4.0
Total
Total (309) 101.3 63 140 38 24.5 56 4.1 2.5 6.0
Iobitridol (154) 101 70 140 35.4 24.5 49 4.2 3.0 6.0
Iomeprol (155) 101.5 63 140 40.6 25.2 56 4.1 2.5 6.0
Centres 1, 2, 4 and 7: constant volumes regardless of patients’ weight, conditions or indication of examination
Centres 3, 5, 6, 8 and 9: volumes adjusted based on patients’ weight, conditions or indication of examination
57795% confidence interval [−2.98%; 3.01%] excluding the
−10% clinical non-inferiority limit; Table 3).
Non-inferiority still holds if the maximum grade (totally
satisfactory) of both products is considered and compared,
as the exact 95% CI (−4.8%; 3.2%) still excludes the −10%
clinical non-inferiority limit (Table 3).
The two examinations which failed to provide sufficient
diagnostic information were performed in patients who had
a history of endovascular and/or surgical treatment of
abdominal arteries.
Image quality according to vascular territories
Of the 2,448 vascular segments assessed in the iobitridol
group and 2,464 in the iomeprol group, 2,319 (94.7%)
and 2,336 (94.8%) were rated as being of “good” to
“excellent” image quality respectively. Differences
between the two groups were statistically not significant
(P=0.5769), and 95% confidence intervals were small
enough to conclude the equivalence of both contrast
agents (Table 4;F i g .2).
Eighty-three segments were not assessable (out of the
FOV, not applicable).
Quality of vascular wall visualisation
The quality of vascular wall visualisation was assessed in
2,448 segments in the iobitridol group and in 2,464 in the
iomeprol group. It was rated good to excellent in 2,064
(84.3%) and 2,049 (83.2%) segments respectively. The
differences between the two groups in this regard were
statistically not significant (P=0.8316), and 95% con-
fidence intervals were small enough to conclude the
equivalence of the two contrast agents (asymptotic 95%
CI [−6.33%; 7.87%]) (Table 5).
Quantification of arterial enhancement
As expected, there was no difference in the mean baseline
values between the two groups (40.0 HU in the iobitridol
group; 40.8 HU in the iomeprol group). After contrast
injection, mean arterial enhancement was 320.4 HU (SD,
93.54; range, 42–638) in the iobitridol group and 353.6 HU
(SD, 95.45; range, 25–770) in the iomeprol group. The
enhancement variation statistically differed between groups
when considering the absolutevariation(P=0.0014; 95% CI
[−53.47; −12.85]). Comparing the relative changes from
baseline to arterial phase, no statistical difference was
observed (P=0.0673; 95% CI [−1.53; 0.053]) (Table 6).
Safety
Three patients reported a total of five non-serious adverse
events,alloccurringaftercontrast agent injection(diarrhoea,
pain,neckrashandswellingintheiobitridolgroup;nauseain
the iomeprol group). Two adverse events (neck rash and
Table 3 Diagnostic efficacy according to patients
Injected product All Statistical test
Iobitridol 350
(n=153)
Iomeprol 400
(n=154)
(n=307)
n % n % n %
MDCT diagnostic efficacy
Not satisfactory/not providing enough information 0 0.0% 1 0.6% 1 0.3%
Not satisfactory/not providing all expected information 1 0.7% 0 0.0% 1 0.3%
Satisfactory/providing sufficient information 3 2.0% 2 1.3% 5 1.6%
Totally satisfactory/providing expected information 149 97.4% 151 98.1% 300 97.7%
MDCT diagnostic efficacy, primary endpoint
Not satisfactory 1 0.7% 1 0.6% 2 0.7% Asympt. 95% CI: [−1.8%; 1.8%]
Totally satisfactory/satisfactory 152 99.3% 153 99.4% 305 99.3% Exact 95% CI: [−2.98%; 3.01%],
P=0.00002
a
MDCT diagnostic efficacy, totally satisfactory
Not totally satisfactory 4 2.6% 3 1.9% 7 2.3% Asympt. 95% CI: [−4.01%;
2.67%]
Totally satisfactory 149 97.4% 151 98.1% 300 97.7% Exact 95% CI: [−4.82%; 3.23%],
P=0.0002
a
Generalised linear model: y = intercept + product
aExact statistical P value for main effect (difference between products ≠ 10%)
578diarrhoea) experienced by the same patient were reported
after the safety follow-up time required (9 and 33 h after the
injection of the contrast agent respectively). All the adverse
events had a favourable outcome, and relationship to the
contrastagentwasassumedforthreeofthem(nausea,rashin
neck and diarrhoea).
Discussion
Although non-invasive MDCT angiography has become
the method of choice for most indications involving the
abdominal and visceral arteries, no general contrast
injection protocol has been established to date [13]. A
number of papers have evaluated the influence of different
parameters for contrast administration, including iodine
concentration, total volume of contrast, injection rate, and
other factors [20, 23–25], on arterial and/or parenchymal
enhancement [13], but very limited general recommenda-
tions on optimised parameters could be gleaned from these
publications. The very simple and basic relation, expressed
as “the higher the iodine application per unit of time, the
higher the enhancement” seems to be an established
general rule for MDCT angiography following most of
Fig. 2 Two examples of abdominal aortic angiograms (maximum
intensity projections, MIP) obtained during the administration
of two contrast agents. The patient in a was examined during
administration of 100 ml iobitridol 350 mgI/ml, and the patient
in b received 100 ml iomeprol 400 mgI/ml. Regardless of
the different total amounts of iodine, both MIPs show excellent
and homogeneous arterial enhancement without visualised
differences
Table 4 Image quality assessments in vessel segments
Injected product All Statistical test
Iobitridol 350 (n=2,448) Iomeprol 400 (n=2,464) (n=4,912)
n % n % n %
Image quality in vessels
– 101
NA (out of the FOV) 32 1.3% 50 2.0% 82 1.7%
Null 64 2.6% 52 2.1% 116 2.4%
Poor 32 1.3% 26 1.1% 58 1.2%
Good 168 6.9% 146 5.9% 314 6.4%
Excellent 2,151 87.9% 2,190 88.9% 4,341 88.4%
Image quality in vessels, good/excellent
–/NA 33 50 83 Asympt. 95% CI: [−3.30%; 1.84%]
Null/poor 96 3.9% 78 3.2% 174 3.5% P=0.5769
a
Good/excellent 2,319 94.7% 2,336 94.8% 4,655 94.8% P=0.3011
b
Image quality in vessels, score
Vessel segments (n) 2,415 2,414 4,829
Mean (SD) 2.824 (0.57) 2.853 (0.53) 2.839 (0.55) Asympt. 95% CI: [−0.109; 0.051]
Median 3.0 3.0 3.0 P=0.4755
a
Min/max 0/3 0/3 0/3 P=0.3103
b
Generalised linear model: y = intercept + product + segment + product × segment (clustered within subjects)
aWald stat. P value for main effect (difference between products ≠ 0)
bWald stat. P value for interaction (difference between products changes with segments)
579these publications [13, 19]. However, the question of
whether this higher iodine flux should be reached by using
a higher iodine concentration or a higher injection flow
remains unclear, despite the number of studies recently
published in this field [20, 25]. A study conducted by Awai
et al. [24] concluded that arterial enhancement could be
improved by increasing the iodine concentration of the
contrast agent. In this study, the injection rate was the same
for both products (0.56 ml/s/kg). Despite the fact that the
results of the latter study are concordant with the study
results reported by Bae et al. [26], it is apparently still
unclear whether a higher concentration of iodine is really
beneficial or not in abdominal MDCT angiography, as an
additional study by Awai et al. [27] reported that faster
injection(4ml/s)ofalower-concentrationagent(300mgI/ml)
led to greater enhancement compared with a slower injection
(3.6 ml/s) of a higher-concentration agent (350 mgI/ml).
In fact, from a clinical point of view, the question of how
to reach the amount of iodine per time needed for
diagnostic images is of limited interest; on the other
hand, the question of how much iodine per unit of time is
really needed for abdominal MDCT angiography seems to
be of greater relevance. Surprisingly, very few recommen-
dations about the minimum iodine flux and minimum total
amount of iodine necessary for abdominal CTangiography
of sufficient image quality and diagnostic confidence have
been published to date [13]. Roos and co-authors have
shown that an iodine concentration of at least 300 mgI/ml
should be recommended [28]. Ho et al. have shown that the
volume of contrast medium can be reduced to a mean
quantity of 107 ml (300 mgI/ml) in abdominal aortic CT
angiography for aortic aneurysms without a significant
decrease in aortic attenuation [29].
From a patient’s point of view, reducing the amount of
iodine as much as possible would help to avoid CIN in
patientsatrisk,astheprobabilityofCINismainlydetermined
by the amount of iodine delivered to patients [14, 16].
In the present study, two contrast agents (different with
regard to their iodine concentration - iobitridol 350 mgI/ml
vs. iomeprol 400 mgI/ml) were compared in a large
population. The aim of this study was expressly not to test
whether a higher-concentration contrast agent is better for
arterial enhancement, as published previously in many
other papers [20, 24, 25], but to demonstrate that the total
amount of iodine can be reduced by more than 12%
without significant disadvantages for diagnostic efficacy,
image quality, or attenuation of MDCT angiography.
The present study statistically demonstrates the non-
inferiority of the 350 mgI/ml iodine concentration vs.
400 mgI/ml in terms of diagnostic efficacy, confirming that
a lower total amount of iodine and a reduced iodine flux for
abdominal CT angiography does not yield inferior diag-
nostic contribution results. Moreover, in a per-patient, as
well as in the more detailed per-segment evaluation, no
significant differences between the two groups were found
with regard to image quality (vessels and vascular walls
Table 5 Image quality assessments in vascular wall segments
Injected product All Statistical test
Iobitridol 350 (n=2,448) Iomeprol 400 (n=2,464) (n=4,912)
n % n % n %
Image quality in vascular walls
– 202
NA (out of the FOV) 32 1.3% 50 2.0% 82 1.7%
Null 77 3.1% 65 2.6% 142 2.9%
Poor 273 11.2% 300 12.2% 573 11.7%
Good 222 9.1% 282 11.4% 504 10.3%
Excellent 1842 75.2% 1767 71.7% 3609 73.5%
Image quality in vascular walls, good/excellent
–/ NA 34 50 84 Asympt. 95% CI: [−6.33%, 7.87%]
Null/poor 350 14.3% 365 14.8% 715 14.6% P=0.8316
a
Good/excellent 2,064 84.3% 2,049 83.2% 4,113 83.7% P=0.1286
b
Image quality in vascular walls, score
Vascular wall segments (n) 2,414 2,414 4,828 Asympt. 95% CI: [−0.118; 0.181]
Mean (SD) 2.586 (0.81) 2.554 (0.81) 2.570 (0.81)
Median 3.0 3.0 3.0 P=0.6789
a
Min/max 0/3 0/3 0/3 P=0.3911
b
Generalised linear model: y = intercept + product + segment + product × segment (clustered within subjects)
aWald stat. P value for main effect (difference between products ≠ 0)
bWald stat. P value for interaction (difference between products changes with segments)
580levels) and relative arterial enhancement, emphasising the
equality of the contrast agents injected for abdominal
MDCT angiography.
The selected study protocol, in which no adaptation of
injection parameters to the iodine rate led to different
iodine fluxes and a broad range of iodine doses being used
(from 24.5 to 56 g, i.e. more than 100%), and the very large
number of examinations rated as being of good or almost
excellent quality in both groups, exemplifies the limited
influence of high iodine concentration and iodine flux on
diagnostic efficacy and image quality of ultra-fast MDCT
angiography using state-of-the-art 64-slice or dual-source
systems (used as single source).
A comparison of these findings with those of previously
published studies is difficult, as most of the other
comparisons between two iodine concentrations have been
performed with a constant iodine flux [20, 24, 25]. The
results presented herein are in contradiction to the
reports, for example, by Awai [24]. One reason for this
difference could be the faster system used in the present
study. Performance of a shorter imaging procedure,
which is initiated slightly later, could lead to a lesser
influence of higher iodine concentrations with regard to
image quality.
These findings allow two major conclusions and
recommendations to be made for the future development
of injection protocols in abdominal MDCT angiography.
Firstly, the role played by contrast material selection seems
to be limited. Secondly, regarding the distribution of total
iodine volumes used by the various investigators in the
present study, there seems to be a general trend towards
using a larger contrast dose than necessary to obtain images
of good or almost excellent quality and high diagnostic
efficacy. Additionally, other parameters become more
important in the case of ultrafast CT angiographies.
Reducing the total amount of contrast to a minimum,
optimizing timing of contrast injection and CT scanning,
and adapting to the extremely short examination times are
mandatory to ensure diagnostic images. Thus, the data
published herein should lead us to revise the examination
protocols used for abdominal MDCTangiography with the
clearly defined purpose of reducing the total amount of
iodine. This will help to reduce the potential for the
development of CIN in patients at risk.
This study is not free of limitations. First, no correlation
with a reference standard was performed. However, as the
aim of the study was to assess the diagnostic efficacy, image
quality and contrast enhancement, rather than the sensitivity
Table 6 Quantification of MDCT enhancement, attenuation variation
Injected product All Statistical tests
Iobitridol 350 (n=1,224) Iomeprol 400 (n=1,232) (n=2,456)
Baseline attenuation (HU)
n 1,162 1,153 2,315
Mean (SD) 40.0 (12.14) 40.8 (12.49) 40.4 (12.32)
Median 40.0 41.0 41.0
Min/max 3/90 3/94 3/94
Post-contrast attenuation (HU)
n 1,196 1,197 2,393
Mean (SD) 320.4 (93.54) 353.6 (95.45) 337.0 (95.93)
Median 306.0 349.0 327.0
Min/max 42/638 25/770 25/770
Attenuation absolute variations from baseline (HU)
n 1,160 1,152 2,312
Mean (SD) 282.3 (93.59) 314.0 (96.20) 298.0 (96.19) Asympt. 95% CI: [−53.47; −12.85]
Median 271.0 309.0 289.0 P=0.0014
a
Min/max −4/588 −12/745 −12/745 P=0.7017
b
Attenuation relative variations from baseline
n 1160 1152 2312
Mean (SD) 8.123 (5.9357) 8.863 (5.4576) 8.492 (5.7132) Asympt. 95% CI: [−1.53; 0.053]
Median 7.043 7.817 7.403 P=0.0673
a
Min/max −0.06/129.00 −0.26/65.83 −0.26/129.00 P=0.6205
b
n Number of vessel segments
Generalised linear model: y = intercept + product + segment + product × segment (clustered within subjects)
aWald stat. P value for main effect (difference between products ≠ 0)
bWald stat. P value for interaction (difference between products changes with segments)
581and specificity values in the detection of a dedicated
pathological condition, the lack of difference between the
two groups seems to be reliable even without a reference
standard. As MDCTangiography is now well-established as
themethodofchoiceforthediagnosisofmostofthedifferent
arterial pathological conditions in the abdomen [4], it would
have been difficult to examine all included patients with an
additional intra-arterial DSA for the purposes of our study.
Another limitation is that only two different iodine
concentrations were used with a limited difference in
iodine concentration. It would be of great interest to know
the exact concentration at which no relevant difference
could be observed, in other words, to assess the minimum
iodine volume the injection could be reduced to without
sacrificing diagnostic efficacy and image quality. Finally, a
limitation of this study could be inherent in the different
injection protocols; the relevant potential confounding
factors (injection rate, volume injected, iodine flux, stent
presence, imaging parameters and clinical indication for
CT) were well-balanced between both groups and had no
statistical impact on the difference between the two
products, leading us to consider that the influence of
iodine concentration has been addressed.
In conclusion, the present study demonstrates the limited
influence of iodine concentration in the range between 350
and 400 mgI/ml on diagnostic efficacy and image quality in
abdominal MDCT angiography with 64-slice and dual-
source systems (used as single source), and the lack of
additional benefit with the use of highly concentrated agents
for this purpose. Furthermore, we showed that more iodine
than necessary is typically injected into patients. In times of
ultrafast CT scanning, continuous adaptation of injection
parameters to the acquisition speed seems to be necessary to
avoidunneededhighamountsofcontrastmaterialontheone
hand while still ensuring sufficient arterial enhancement on
the other hand. The results of the present study underline the
limited influence of high iodine concentration on diagnostic
image quality and exemplify the still existing space for
improvement in contrast injection protocols. Based on the
results of the present study, the amount of contrast can be
reduced by using ultrafast equipment without sacrificing
image quality and/or diagnostic efficacy. Further studies
would be of interest to evaluate the minimum amount of
iodine needed for diagnostic abdominal MDCTangiograms.
Finally, the excellent safety, robustness and reproducibility
of abdominal MDCT angiography was shown in a clinical
setting by the very small number of adverse events and very
few examinations of limited quality. This underlines the
outstanding role played by MDCT angiography in the
diagnosis of diseases of the abdominal arteries.
Open Access This article is distributed under the terms of the
Creative Commons Attribution Noncommercial License which
permits any noncommercial use, distribution, and reproduction in
any medium, provided the original author(s) and source are credited.
References
1. Glockner JF, Vrtiska TJ (2007) Renal
MR and CT angiography: current
concepts. Abdom Imaging 32:407–420
2. Puchner S, Stadler A, Minar E,
Lammer J, Bucek RA (2007)
Multidetector CT angiography in the
follow-up of patients treated with renal
artery stents: value of different
reformation techniques compared with
axial source images. J Endovasc Ther
14:387–394
3. Saba L, Caddeo G, Sanfilippo R,
Montisci R, Mallarini G (2007)
Multidetector-row CT angiography
diagnostic sensitivity in evaluation of
renal artery stenosis: comparison
between multiple reconstruction
techniques. J Comput Assist Tomogr
31:712–716
4. Rau MM, Setty BN, Blake MA,
Ouellette-Piazzo K, Hahn PF, Sahani
DV (2007) Evaluation of renal trans-
plant donors with 16-section multi-
detector CT angiography: comparison
of contrast media with low and high
iodine concentrations. J Vasc Interv
Radiol 18:603–609
5. Fleischmann D (2003) Multiple
detector-row CT angiography of the
renal and mesenteric vessels. Eur J
Radiol 45:S79–S87
6. Horton KM, Fishman EK (2007)
Multidetector CT angiography in the
diagnosis of mesenteric ischemia.
Radiol Clin North Am 45:275–288
7. Willmann JK, Baumert B, Schertler T,
Wildermuth S, Pfammatter T, Verdun
FR, Seifert B, Marincek B, Böhm T
(2005) Aortoiliac and lower extremity
arteries assessed with 16-detector row
CT angiography: prospective
comparison with digital subtraction
angiography. Radiology 236:
1083–1093
8. Yu T, Zhu X, Tang L, Wang D, Saad N
(2007) Review of CT angiography of
aorta. Radiol Clin North Am 45:461–
483
9. Teutelink A, Muhs BE, Vincken KL,
Bartels LW, Cornelissen SA, van
Herwaarden JA, Prokop M, Moll FL,
Verhagen HJ (2007) Use of dynamic
computed tomography to evaluate pre-
and postoperative aortic changes in
AAA patients undergoing endovascular
aneurysm repair. J Endovasc Ther
14:44–49
10. Michaely HJ, Kramer H, Dietrich O,
Nael K, Lodemann KP, Reiser MF,
Schoenberg SO (2007) Intraindividual
comparison of high-spatial-resolution
abdominal MR angiography at 1.5 T
and 3.0 T: initial experience. Radiology
244:907–913
11. Sutter R, Nanz D, Lutz AM,
Pfammatter T, Seifert B, Struwe A,
Heilmaier C, Weishaupt D, Marincek
B, Willmann JK (2007) Assessment of
aortoiliac and renal arteries: MR
angiography with parallel acquisition
versus conventional MR angiography
and digital subtraction angiography.
Radiology 245:276–284
58212. Attenberger UI, Michaely HJ,
Wintersperger BJ, Sourbron SP,
Lodemann KP, Reiser MF, Schoenberg
SO (2008) Three-dimensional contrast-
enhanced magnetic-resonance
angiography of the renal arteries:
interindividual comparison of
0.2 mmol/kg gadobutrol at 1.5 T and
0.1 mmol/kg gadobenate dimeglumine
at 3.0 T. Eur Radiol 18:1260–1268
13. Johnson PT, Fishman EK (2006) IV
contrast selection for MDCT: current
thoughts and practice. AJR Am J
Roentgenol 186:406–415
14. Katzberg RW, Barrett BJ (2007) Risk of
iodinated contrast material-induced
nephropathy with intravenous
administration. Radiology 243:622–628
15. Thomsen HS, Morcos SK, Barrett BJ
(2008) Contrast-induced nephropathy:
the wheel has turned 360 degrees. Acta
Radiol 49:646–657
16. Nyman U, Almén T, Aspelin P,
Hellström M, Kristiansson M, Sterner
G (2005) Contrast-medium-induced
nephropathy correlated to the ratio
between dose in gram iodine and
estimated GFR in ml/min. Acta Radiol
46:830–842
17. Fleischmann D, Rubin GD, Bankier
AA, Hittmair K (2000) Improved
uniformity of aortic enhancement with
customized contrast medium injection
protocols at CT angiography.
Radiology 214:363–371
18. Hittmair K, Fleischmann D (2001)
Accuracy of predicting and controlling
time-dependent aortic enhancement
from a test bolus injection. J Comput
Assist Tomogr 25:287–294
19. Fleischmann D (2005) How to design
injection protocols for multiple
detector-row CT angiography
(MDCTA). Eur Radiol 15:E60–E65
20. Behrendt FF, Mahnken AH, Keil S, Das
M, Hohl C, Bauer D, Seidensticker P,
Jost E, Wildberger JE, Günther RW,
Mühlenbruch G (2008) Contrast
enhancement in multidetector-row
computed tomography (MDCT) of the
abdomen: intraindividual comparison
of contrast media containing 300 mg
versus 370 mg iodine per ml. Eur
Radiol 18:1199–1205
21. Petersein J, Peters CR, Wolf M, Hamm
B (2003) Results of the safety and
efficacy of iobitridol in more than
61,000 patients. Eur Radiol 13:2006–
2011
22. Valentini AL, Tartaglione T, Monti L,
Marano P (1994) Iomeprol versus
iopamidol in contrast-enhanced
computed tomography of thoracic and
abdominal organs. Eur J Radiol 18:
S88–S92
23. Furuta A, Ito K, Fujita T, Koike S,
Shimizu A, Matsunaga N (2004)
Hepatic enhancement in multiphasic
contrast-enhanced MDCT: comparison
of high- and low-iodine-concentration
contrast medium in same patients with
chronic liver disease. AJR Am J
Roentgenol 183:157–162
24. Awai K, Takada K, Onishi H, Hori S
(2002) Aortic and hepatic enhancement
and tumor-to-liver contrast: analysis of
the effect of different concentrations of
contrast material at multi-detector
row helical CT. Radiology 224:757–
763
25. SuzukiH,OshimaH,ShirakiN,IkeyaC,
Shibamoto Y (2004) Comparison of two
contrast materials with different iodine
concentrations in enhancing the density
oftheaorta,portalveinandliveratmulti-
detectorrowCT:arandomizedstudy.Eur
Radiol 14:2099–2104
26. Bae KT, Heiken JP, Brink JA (1998)
Aortic and hepatic peak enhancement at
CT: effect of contrast medium injection
rate-pharmacokinetic analysis and
experimental porcine model. Radiology
206:455–464
27. Awai K, Inoue M, Yagyu Y, Watanabe
M, Sano T, Nin S, Koike R, Nishimura
Y, Yamashita Y (2004) Moderate
versus high concentration of contrast
material for aortic and hepatic
enhancement and tumor-to-liver
contrast at multi-detector row CT.
Radiology 233:682–688
28. Roos JE, Desbiolles LM, Weishaupt D,
Wildermuth S, Hilfiker PR, Marincek
B, Boehm T (2004) Multi-detector row
CT: effect of iodine dose reduction on
hepatic and vascular enhancement.
Rofo 176:556–563
29. Ho LM, Nelson RC, Thomas J,
Gimenez EI, DeLong DM (2004)
Abdominal aortic aneurysms at
multi-detector row helical CT: optimi-
zation with interactive determination of
scanning delay and contrast medium
dose. Radiology 232:854–859
583